18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Apr 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging tool called 18F-FAPI-YQ104, which helps doctors see and diagnose certain types of tumors, including lung, pancreatic, thyroid cancers, and neuroendocrine tumors. The goal is to find out if this new tool is safe to use and how effective it is in spotting tumors that other imaging methods, like CT or MRI scans, might miss.

To participate, volunteers should be between 18 and 75 years old and have been diagnosed with one of the targeted cancers, confirmed by imaging tests. They should also be in good health overall, meaning their kidney and liver functions are normal and they don’t have severe health issues that could interfere with the study. Participants will receive the new imaging tool and will be monitored for safety and effectiveness. This trial is currently looking for volunteers, and those interested should discuss this opportunity with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - 1. Volunteer for the trial, with the patient or their legal guardian signing the informed consent form; 2. Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends; 3. Other imaging examination methods (CT, MRI, etc.) revealed tumor occupying lesions; 4. Patients with lung cancer, thyroid cancer, pancreatic cancer, melanoma, and neuroendocrine tumors who can obtain the final pathological results.
• • 5. Kidney: GFR \> 50 ml/min, ERPF \> 280 ml/min, platelet count (PLT) \> 75,000/μL, white blood cell (WBC) \> 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 3 times the normal value.
• Exclusion Criteria:
• • 1. Individuals with a history of allergies to similar drugs (drugs with similar chemical or biological components to FAPI), allergic constitution, or current allergic diseases; 2. Those who are currently conducting clinical research on other drugs or have participated in any clinical research on drugs (excluding vitamins and minerals); 3. There are other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other system diseases); 4. Red blood cell RBC\<4 × 1012, white blood cell WBC\<3 × 109, hemoglobin\<110g/L, PLT\<75000×109； 5. Significant abnormalities in liver and kidney function, with GFR less than 50 ml/min; 6. Tumor burden greater than 50%, or significant spinal cord compression; 7. Expected survival period is less than six months; Chemotherapy within June; 8. Having severe acute comorbidities or severe refractory mental disorders; 9. Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study); 10. Patients whose physical condition is not suitable for radiation examination; 11. Other situations that researchers consider unsuitable for participating in the experiment.